Enhancing islet engraftment with rosiglitazone

B. R.S. Hsu*, S. H. Fu, K. W. Ku, T. Y. Yang, J. H. Juang, S. T. Chen

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

8 Scopus citations


To study the role of a peroxisome proliferator-activated receptor agonist, rosiglitazone, on islet engraftment, streptozotocin-induced diabetic C57BL/6 mice were fed daily rosiglitazone (2.4 mg/kg) for 9 and 31 days starting 2 days before transplantation with 75 and 150 syngeneic islets, respectively. After receiving 75 islets and 9 days of rosiglitazone, half of the treated diabetic mice became normoglycemic at 4 weeks, while none were normoglycemic among those mice that did not receive treatment. After transplanting 150 islets and receiving 31 days of rosiglitazone, 80% of the treated diabetic mice became normoglycemic while the incidence was only 25% for the controls. The insulin content of the islet grafts in the rosiglitazone groups was 0.8 times (75-islet group) and 1.3 times (150-islet group) higher than that of control mice. The insulin content of pancreatic remnants did not differ significantly among all groups. An in vitro study revealed that the glucose-stimulated insulin secretion and insulin content of cultured islets was not different in the presence versus absence of 4.5 or 22.5 μmol/L rosiglitazone. In vitro study revealed that rosiglitazone inhibited the lipopolysaccharide-induced secretion of interleukin-1 beta and interferon-gamma from peritoneal exudate cells. In conclusion, our data suggest that short-term administration of rosiglitazone enhances islet engraftment.

Original languageEnglish
Pages (from-to)245-247
Number of pages3
JournalTransplantation Proceedings
Issue number1
StatePublished - 2005
Externally publishedYes


Dive into the research topics of 'Enhancing islet engraftment with rosiglitazone'. Together they form a unique fingerprint.

Cite this